NK cell dysfunction with down-regulated CD16 and up-regulated CD56 molecules in patients with esophageal squamous cell carcinoma

Diseases of the Esophagus

Volumn 23, Issue 8, 2010, Pages 675-681

  Watanabe, M ^a   Kono, K ^a   Kawaguchi, Y ^a   Mizukami, Y ^a   Mimura, K ^a   Maruyama, T ^a   Izawa, S ^a   Fujii, H ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

ADCC; CD16; CD56; Cetuximab; NK; TGF beta

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

AGED; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ARTICLE; CANCER SURGERY; CLINICAL ARTICLE; DOWN REGULATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; HUMAN CELL; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; UPREGULATION;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD56; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; ESOPHAGEAL NEOPLASMS; HUMANS; KILLER CELLS, NATURAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, IGG; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 78649515791     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2010.01073.x     Document Type: Article

References (26)

1. Kleinberg L, Forastiere A A. Chemoradiation in the management of esophageal cancer. J Clin Oncol 2007; 5: 4110-7.
2. Ando N, Iizuka T, Ide H et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study - JCOG9204. J Clin Oncol 2003; 21: 4592-6.
3. Akiyama H, Tsurumaru M, Udagawa H, Kajiyama Y. Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 1994; 220: 364-72.
4. Sato E, Olson S H, Ahn J et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005; 102: 18538-43.
5. Strater J, Hinz U, Hasel C et al. Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease. Gut 2005; 54: 661-5.
6. Kono K, Kawaida H, Takahashi A et al. CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 2006; 55: 1064-71.
7. Yoshioka T, Miyamoto M, Cho Y et al. Infiltrating regulatory T cell numbers is not a factor to predict patient's survival in oesophageal squamous cell carcinoma. Br J Cancer 2008; 98: 1258-63.
8. Milano F, Jorritsma T, Rygiel A M et al. Expression pattern of immune suppressive cytokines and growth factors in oesophageal adenocarcinoma reveal a tumour immune escape-promoting microenvironment. Scand J Immunol 2008; 68: 616-23.
9. Mimura K, Kono K, Hanawa M et al. Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin Cancer Res 2005; 11: 4898-904.
10. Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fujii H. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 2007; 120: 781-7.
11. Kawaguchi Y, Kono K, Mimura K et al. Targeting EGFR and HER-2 with Cetuximab- and Trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br J Cancer 2007; 97: 494-501.
12. Fan Q R, Mosyak L, Winter C C, Wagtmann N, Long E O, Wiley D C. Structure of the inhibitory receptor for human natural killer cells resembles haematopoietic receptors. Nature 1997; 389: 96-100.
13. Tsuruma T, Yagihashi A, Hirata K et al. Interleukin-10 reduces natural killer (NK) sensitivity of tumor cells by downregulating NK target structure expression. Cell Immunol 1999; 198: 103-10.
14. Konjević G, Mirjacić Martinović K, Vuletić A et al. Low expression of CD161 and NKG2D activating NK receptor is associated with impaired NK cell cytotoxicity in metastatic melanoma patients. Clin Exp Metastasis 2007; 24: 1-11.
15. Lee J C, Lee K M, Kim D W, Heo D S. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 2004; 172: 7335-40.
16. Cooper M A, Fehniger T A, Caligiuri M A. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22: 633-40.
17. Kono K, Salazar-Onfray F, Petersson M et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell and natural killer cell-mediated cytotoxicity. Eur J Immunol 1996; 26: 1308-13.
18. Kono K, Ressing M E, Brandt R M et al. Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin Cancer Res 1996; 2: 1825-8.
19. Batoni G, Esin S, Favilli F et al. Human CD56bright and CD56dim natural killer cell subsets respond differentially to direct stimulation with Mycobacterium bovis bacillus Calmette-Guérin. Scand J Immunol 2005; 62: 498-506.
20. Harlin H, Hanson M, Johansson C C et al. The CD16- CD56(bright) NK cell subset is resistant to reactive oxygen species produced by activated granulocytes and has higher antioxidative capacity than the CD16+ CD56(dim) subset. J Immunol 2007; 179: 4513-9.
21. Schierloh P, Yokobori N, Alemán M et al. Increased susceptibility to apoptosis of CD56dimCD16+ NK cells induces the enrichment of IFN-gamma-producing CD56bright cells in tuberculous pleurisy. J Immunol 2005; 175: 6852-60.
22. Bauernhofer T, Kuss I, Henderson B, Baum A S, Whiteside T L. Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer. Eur J Immunol 2003; 33: 119-24.
23. Keskin D B, Allan D S, Rybalov B et al. TGFbeta promotes conversion of CD16+ peripheral blood NK cells into CD16- NK cells with similarities to decidual NK cells. Proc Natl Acad Sci USA 2007; 104: 3378-83.
24. Gholamin M, Moaven O, Memar B et al. Overexpression and interactions of interleukin-10, transforming growth factor beta, and vascular endothelial growth factor in esophageal squamous cell carcinoma. World J Surg 2009; 33: 1439-45.
25. Clynes R A, Towers T L, Presta L G, Ravetch J V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6: 443-6.
26. Varchetta S, Gibelli N, Oliviero B et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res 2007; 67: 11991-9.